J&J buys Actelion for US$30bn

JOHNSON & JOHNSON (J&J) has agreed to buy Swiss biotech firm Actelion for US$30bn, while spinning off the company’s drug development pipeline.

Recent Editions

Catch up on the latest news, views and jobs from The Chemical Engineer. Below are the four latest issues. View a wider selection of the archive from within the Magazine section of this site.